The global leadless pacemakers market was valued at USD 1.28 billion in 2025. It is estimated at USD 1.46 billion in 2026 and is projected to reach USD 4.87 billion by 2036, growing at a CAGR of 12.8% over the 2026-2036 forecast period. This report provides a detailed assessment of the market, covering bradyarrhythmia epidemiology, pacemaker implant volumes and leadless penetration, device technology, clinical evidence, regulation and reimbursement, pricing and health economics, the value chain, and the competitive landscape.
Leadless pacemakers are self-contained capsules that hold the battery, circuitry, and electrodes in one unit and are placed inside the heart with a catheter passed through the femoral vein. Because they need no transvenous lead and no chest pocket, they avoid the parts of a conventional system that cause most device complications. The study covers single-chamber devices for the right ventricle or right atrium, dual-chamber and AV-synchronous systems, modular systems that work with other implants such as subcutaneous defibrillators, and leadless resynchronization systems that pace the left ventricle from within. Devices differ in fixation (nitinol tines or an active helix), battery life, retrievability, and communication features. Value is tracked at the manufacturer level for both the implants and their delivery catheters, while conventional transvenous pacemakers fall outside the scope.
Leadless pacing has moved well beyond early adoption since April 2016, when Medtronic's Micra became the first leadless device to win U.S. FDA approval, and Medtronic reported that nearly 200,000 patients worldwide had received a Micra device when its next-generation Micra AV2 and Micra VR2 systems were cleared. Safety data from routine practice are encouraging: according to a Micra post-approval registry covering 795 patients at 97 centers, implant success reached 99.6% and the 30-day major complication rate was 1.5%, even though about 87% of the physicians had not implanted the device before. According to Abbott, more than 80% of patients who need a pacemaker require stimulation of both upper and lower right heart chambers, which is the population dual-chamber leadless systems now address.
Leadless devices are priced well above mature conventional pacemakers, and in many European, Asian, and Latin American health systems, budgets and tenders limit their use to high-risk patients. Until recently, leadless systems could only pace the right ventricle, and they still cannot deliver conduction system pacing. Implantation through large-bore femoral catheters carries a risk of cardiac perforation, which the FDA highlighted in a 2021 letter to healthcare providers, and long-term management remains uncertain because devices become encapsulated over time and younger patients may need several devices. Other challenges include training implanters, battery life in patients who pace often or use device-to-device communication, competition from left bundle branch area and His bundle pacing with conventional leads, and affordability in markets such as China, where volume-based procurement has driven down conventional pacemaker prices.
Modular systems are a major opportunity: Boston Scientific has built its EMPOWER device to work in tandem with the company's subcutaneous ICD, and the company presented MODULAR ATP trial results in 2024. Leadless resynchronization and future leadless conduction system pacing could extend the technology into heart failure, as shown by the April 2025 FDA approval of EBR Systems' WiSE system, and launches in emerging markets such as India are widening access. Key trends include the shift toward dual-chamber pacing, designs built for retrieval and lifetime management, smaller devices with longer battery life, and communicating multi-device ecosystems.
Based on product, the market is segmented into single-chamber (ventricular VVIR and atrial AAIR), dual-chamber & AV-synchronous (two-device dual-chamber systems and single-device AV-synchronous systems), modular systems, and leadless CRT. Single-chamber devices are expected to hold the largest share in 2026, reflecting the large installed base built since 2016, continued implants of Micra VR2 and AVEIR VR, and their established role in patients with permanent atrial fibrillation or low pacing needs. Dual-chamber & AV-synchronous systems are expected to grow at the highest CAGR during the forecast period, as AVEIR DR and Micra AV2 open leadless therapy to the large majority of patients who need atrial and ventricular coordination. Modular systems and leadless CRT are earlier-stage categories that could expand the market into defibrillator and heart failure patients.
The implant site analysis covers the right ventricle, the right atrium, and the left ventricular endocardium. The right ventricle is expected to account for the largest share in 2026, since every single-chamber ventricular and AV-synchronous device is placed there and it forms the ventricular half of two-device systems. The right atrium is expected to grow at the highest CAGR, supported by atrial devices such as AVEIR AR, which serve both as the upper half of dual-chamber systems and as stand-alone therapy in sick sinus syndrome. The left ventricular endocardium is a newer site used by leadless resynchronization systems such as WiSE.
Based on fixation mechanism, the market is segmented into tines and helix. Tine-based designs anchor the capsule to the heart wall with flexible nitinol tines, while helix designs use an active screw that is driven into the tissue. The fixation method shapes implant technique, positioning, and the approach to retrieval when a device reaches the end of its life, so it is weighed alongside battery longevity, retrievability, and communication features when physicians select a system. The report sizes both mechanisms and the factors behind their use.
By indication, the report covers atrioventricular block, sick sinus syndrome, atrial fibrillation with bradycardia, and heart failure. Atrioventricular block is expected to account for the largest share in 2026, as it is a leading reason for permanent pacing and is well served by ventricular and AV-synchronous leadless devices. Sick sinus syndrome is expected to grow at the highest CAGR, as atrial and dual-chamber leadless systems now allow patients who depend on atrial pacing to avoid leads. Heart failure is an emerging indication tied to leadless resynchronization.
By end user, the study covers hospitals and cardiac specialty centers & outpatient facilities. Hospitals are expected to account for the larger share in 2026, as leadless implants require electrophysiology labs, imaging, and surgical backup in case of perforation. Cardiac specialty centers & outpatient facilities are expected to register the higher CAGR, as shorter procedures without a surgical pocket support same-day discharge and experience with the technique spreads beyond large hospitals.
North America is expected to remain the largest regional market in 2026, owing to early FDA approvals, mature reimbursement, wide use by electrophysiologists, and the home base of the leading device makers. The U.S. was the first market for Micra in 2016 and AVEIR VR in 2022, later approved AVEIR DR, Micra AV2, and Micra VR2, and cleared EBR Systems' WiSE system in April 2025, while Boston Scientific is developing EMPOWER. Canada's aging population adds to demand.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by fast-aging populations, expanding electrophysiology capacity, and new launches. Japan is an established leadless market with one of the world's oldest populations, Abbott introduced AVEIR VR in India in May 2024 and the country's first dual-chamber leadless pacemaker in October 2025, and Chinese firms including MicroPort and Lepu Medical are working on local devices that could lower prices. Europe holds a significant share, with large pacing populations in Germany, France, Italy, Spain, and the U.K., CE Mark for Micra AV2 and VR2 in January 2024, and local developers Biotronik and Cairdac, although tenders often favor conventional devices. In Latin America, Brazil, Mexico, and Argentina are price-sensitive markets where private hospitals lead adoption, while in the Middle East & Africa, Saudi Arabia, the UAE, and Israel have advanced cardiac centers and high diabetes rates that favor infection-avoiding devices.
The market is highly concentrated, with Medtronic and Abbott as the leading suppliers. Boston Scientific is developing a modular leadless system, EBR Systems offers leadless resynchronization, European and Chinese companies are developing new devices, and Integer Holdings supplies components. Competition is based on pacing-mode range, battery life, ease of retrieval, safety and implant outcomes, device-to-device links, supporting data, price, and training support. Leading companies are adding dual-chamber and AV-synchronous functions, extending battery life, designing for retrieval, building multi-device systems, and entering emerging markets. Recent milestones include the January 2024 CE Mark for Micra AV2 and VR2, Boston Scientific's 2024 MODULAR ATP results, the April 2025 FDA approval of WiSE, and Abbott's October 2025 launch of AVEIR DR in India.
Key companies profiled in the report include Medtronic plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), EBR Systems, Inc. (U.S.), Biotronik SE & Co. KG (Germany), MicroPort CRM (China/France), Lepu Medical Technology (Beijing) Co., Ltd. (China), Cairdac (France), and Integer Holdings Corporation (U.S.).
Leadless pacemakers are self-contained capsules that hold the battery, circuitry, and electrodes in one unit and are placed inside the heart with a catheter passed through the femoral vein. Because they need no transvenous lead and no chest pocket, they avoid the parts of a conventional system that cause most device complications. The study covers single-chamber devices for the right ventricle or right atrium, dual-chamber and AV-synchronous systems, modular systems that work with other implants such as subcutaneous defibrillators, and leadless resynchronization systems that pace the left ventricle from within. Devices differ in fixation (nitinol tines or an active helix), battery life, retrievability, and communication features. Value is tracked at the manufacturer level for both the implants and their delivery catheters, while conventional transvenous pacemakers fall outside the scope.
Leadless pacing has moved well beyond early adoption since April 2016, when Medtronic's Micra became the first leadless device to win U.S. FDA approval, and Medtronic reported that nearly 200,000 patients worldwide had received a Micra device when its next-generation Micra AV2 and Micra VR2 systems were cleared. Safety data from routine practice are encouraging: according to a Micra post-approval registry covering 795 patients at 97 centers, implant success reached 99.6% and the 30-day major complication rate was 1.5%, even though about 87% of the physicians had not implanted the device before. According to Abbott, more than 80% of patients who need a pacemaker require stimulation of both upper and lower right heart chambers, which is the population dual-chamber leadless systems now address.
Market Dynamics
The complications of conventional pacemakers are the main reason clinicians turn to leadless devices. Leads can fracture, dislodge, block veins, or interfere with the tricuspid valve, and pockets can bleed or become infected, sometimes requiring difficult lead extraction. Population aging adds to demand, since sick sinus syndrome and AV block become much more common later in life and many elderly patients have diabetes, kidney disease, or frailty that raises infection risk; the World Health Organization expects people aged 60 and over to make up one-sixth of the global population by 2030. The arrival of dual-chamber leadless pacing, led by Abbott's AVEIR DR and Medtronic's Micra AV2, has widened the eligible population, and a growing body of trial and registry data, such as the LEADLESS II study behind the 2022 FDA approval of AVEIR VR, supports broader use.Leadless devices are priced well above mature conventional pacemakers, and in many European, Asian, and Latin American health systems, budgets and tenders limit their use to high-risk patients. Until recently, leadless systems could only pace the right ventricle, and they still cannot deliver conduction system pacing. Implantation through large-bore femoral catheters carries a risk of cardiac perforation, which the FDA highlighted in a 2021 letter to healthcare providers, and long-term management remains uncertain because devices become encapsulated over time and younger patients may need several devices. Other challenges include training implanters, battery life in patients who pace often or use device-to-device communication, competition from left bundle branch area and His bundle pacing with conventional leads, and affordability in markets such as China, where volume-based procurement has driven down conventional pacemaker prices.
Modular systems are a major opportunity: Boston Scientific has built its EMPOWER device to work in tandem with the company's subcutaneous ICD, and the company presented MODULAR ATP trial results in 2024. Leadless resynchronization and future leadless conduction system pacing could extend the technology into heart failure, as shown by the April 2025 FDA approval of EBR Systems' WiSE system, and launches in emerging markets such as India are widening access. Key trends include the shift toward dual-chamber pacing, designs built for retrieval and lifetime management, smaller devices with longer battery life, and communicating multi-device ecosystems.
Segment Analysis
The report analyzes the market by product, implant site, fixation mechanism, indication, end user, and geography, helping stakeholders identify where adoption is concentrated and where it is expanding.Based on product, the market is segmented into single-chamber (ventricular VVIR and atrial AAIR), dual-chamber & AV-synchronous (two-device dual-chamber systems and single-device AV-synchronous systems), modular systems, and leadless CRT. Single-chamber devices are expected to hold the largest share in 2026, reflecting the large installed base built since 2016, continued implants of Micra VR2 and AVEIR VR, and their established role in patients with permanent atrial fibrillation or low pacing needs. Dual-chamber & AV-synchronous systems are expected to grow at the highest CAGR during the forecast period, as AVEIR DR and Micra AV2 open leadless therapy to the large majority of patients who need atrial and ventricular coordination. Modular systems and leadless CRT are earlier-stage categories that could expand the market into defibrillator and heart failure patients.
The implant site analysis covers the right ventricle, the right atrium, and the left ventricular endocardium. The right ventricle is expected to account for the largest share in 2026, since every single-chamber ventricular and AV-synchronous device is placed there and it forms the ventricular half of two-device systems. The right atrium is expected to grow at the highest CAGR, supported by atrial devices such as AVEIR AR, which serve both as the upper half of dual-chamber systems and as stand-alone therapy in sick sinus syndrome. The left ventricular endocardium is a newer site used by leadless resynchronization systems such as WiSE.
Based on fixation mechanism, the market is segmented into tines and helix. Tine-based designs anchor the capsule to the heart wall with flexible nitinol tines, while helix designs use an active screw that is driven into the tissue. The fixation method shapes implant technique, positioning, and the approach to retrieval when a device reaches the end of its life, so it is weighed alongside battery longevity, retrievability, and communication features when physicians select a system. The report sizes both mechanisms and the factors behind their use.
By indication, the report covers atrioventricular block, sick sinus syndrome, atrial fibrillation with bradycardia, and heart failure. Atrioventricular block is expected to account for the largest share in 2026, as it is a leading reason for permanent pacing and is well served by ventricular and AV-synchronous leadless devices. Sick sinus syndrome is expected to grow at the highest CAGR, as atrial and dual-chamber leadless systems now allow patients who depend on atrial pacing to avoid leads. Heart failure is an emerging indication tied to leadless resynchronization.
By end user, the study covers hospitals and cardiac specialty centers & outpatient facilities. Hospitals are expected to account for the larger share in 2026, as leadless implants require electrophysiology labs, imaging, and surgical backup in case of perforation. Cardiac specialty centers & outpatient facilities are expected to register the higher CAGR, as shorter procedures without a surgical pocket support same-day discharge and experience with the technique spreads beyond large hospitals.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 20 countries and four rest-of-region groups. The regional analysis considers population aging, pacing volumes, regulatory approvals, reimbursement and tender practices, electrophysiology capacity, and product launches.North America is expected to remain the largest regional market in 2026, owing to early FDA approvals, mature reimbursement, wide use by electrophysiologists, and the home base of the leading device makers. The U.S. was the first market for Micra in 2016 and AVEIR VR in 2022, later approved AVEIR DR, Micra AV2, and Micra VR2, and cleared EBR Systems' WiSE system in April 2025, while Boston Scientific is developing EMPOWER. Canada's aging population adds to demand.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by fast-aging populations, expanding electrophysiology capacity, and new launches. Japan is an established leadless market with one of the world's oldest populations, Abbott introduced AVEIR VR in India in May 2024 and the country's first dual-chamber leadless pacemaker in October 2025, and Chinese firms including MicroPort and Lepu Medical are working on local devices that could lower prices. Europe holds a significant share, with large pacing populations in Germany, France, Italy, Spain, and the U.K., CE Mark for Micra AV2 and VR2 in January 2024, and local developers Biotronik and Cairdac, although tenders often favor conventional devices. In Latin America, Brazil, Mexico, and Argentina are price-sensitive markets where private hospitals lead adoption, while in the Middle East & Africa, Saudi Arabia, the UAE, and Israel have advanced cardiac centers and high diabetes rates that favor infection-avoiding devices.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with industry leaders, market differentiators, vanguards, and emerging companies, and market share/rank analysis for 2025. Company profiles cover business overview, financial overview, product portfolio, strategic developments, and SWOT analysis.The market is highly concentrated, with Medtronic and Abbott as the leading suppliers. Boston Scientific is developing a modular leadless system, EBR Systems offers leadless resynchronization, European and Chinese companies are developing new devices, and Integer Holdings supplies components. Competition is based on pacing-mode range, battery life, ease of retrieval, safety and implant outcomes, device-to-device links, supporting data, price, and training support. Leading companies are adding dual-chamber and AV-synchronous functions, extending battery life, designing for retrieval, building multi-device systems, and entering emerging markets. Recent milestones include the January 2024 CE Mark for Micra AV2 and VR2, Boston Scientific's 2024 MODULAR ATP results, the April 2025 FDA approval of WiSE, and Abbott's October 2025 launch of AVEIR DR in India.
Key companies profiled in the report include Medtronic plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), EBR Systems, Inc. (U.S.), Biotronik SE & Co. KG (Germany), MicroPort CRM (China/France), Lepu Medical Technology (Beijing) Co., Ltd. (China), Cairdac (France), and Integer Holdings Corporation (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global leadless pacemakers market through 2036.
- Explains how lead and pocket complications, population aging, and dual-chamber leadless pacing are shaping adoption.
- Assesses the impact of device cost, perforation risk, battery life, and lifetime device management on clinical uptake.
- Identifies high-growth opportunities across product, implant site, fixation mechanism, indication, end user, and region.
- Tracks emerging technologies such as modular pacing-defibrillation systems, leadless resynchronization, and leadless conduction system pacing.
- Benchmarks leading manufacturers on product portfolios, clinical evidence, approvals, and market position.
- Supports product development, market access, pricing, partnership, and investment decisions for device makers, component suppliers, providers, and investors.
Key Questions Answered
- How large is the global leadless pacemakers market today, and how will it grow through 2036?
- How quickly will dual-chamber and AV-synchronous leadless systems replace conventional dual-chamber pacemakers?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do safety data, perforation risk, and retrieval strategies influence physician and hospital choices?
- Which product, implant site, fixation mechanism, indication, and end user segments will grow the fastest?
- What role will modular systems and leadless resynchronization play in expanding the market?
- Which regions and countries offer the most attractive opportunities?
- Who are the leading companies in the market, and how do they compare?
- What approvals, launches, and clinical trials are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Leadless Pacemakers Market, by Product
6. Leadless Pacemakers Market, by Implant Site
7. Leadless Pacemakers Market, by Fixation Mechanism
8. Leadless Pacemakers Market, by Indication
9. Leadless Pacemakers Market, by End User
10. Leadless Pacemakers Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corporation
- EBR Systems, Inc.
- Biotronik SE & Co. KG
- MicroPort CRM
- Lepu Medical Technology
- Cairdac
- Integer Holdings Corporation
